Xeroderma Pigmentosum Group D Protein
"Xeroderma Pigmentosum Group D Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A DNA helicase that is a component of TRANSCRIPTION FACTOR TFIIH. It plays an essential role in NUCLEOTIDE EXCISION REPAIR, and mutations in this protein are associated with XERODERMA PIGMENTOSUM.
Descriptor ID |
D051759
|
MeSH Number(s) |
D08.811.277.040.025.159.500 D08.811.399.340.500 D12.776.260.775.875.875.500 D12.776.930.930.875.875.500
|
Concept/Terms |
Xeroderma Pigmentosum Group D Protein- Xeroderma Pigmentosum Group D Protein
- Excision Repair Cross-Complementing Rodent Repair Deficiency, Group 2 Protein
- Excision Repair Cross Complementing Rodent Repair Deficiency, Group 2 Protein
- Xeroderma Pigmentosum Complementation Group D Protein
- ERCC2 Protein
|
Below are MeSH descriptors whose meaning is more general than "Xeroderma Pigmentosum Group D Protein".
Below are MeSH descriptors whose meaning is more specific than "Xeroderma Pigmentosum Group D Protein".
This graph shows the total number of publications written about "Xeroderma Pigmentosum Group D Protein" by people in this website by year, and whether "Xeroderma Pigmentosum Group D Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 | 2004 | 0 | 1 | 1 | 2015 | 0 | 1 | 1 | 2024 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Xeroderma Pigmentosum Group D Protein" by people in Profiles.
-
Iyer G, Tangen CM, Sarfaty M, Regazzi AM, Lee IL, Fong M, Choi W, Dinney CPN, Flaig TW, Thompson IM, Lerner SP, McConkey DJ, Rosenberg JE. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
-
Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Scott Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner SP, Flaig TW, McConkey DJ. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
-
Luo J, Cimermancic P, Viswanath S, Ebmeier CC, Kim B, Dehecq M, Raman V, Greenberg CH, Pellarin R, Sali A, Taatjes DJ, Hahn S, Ranish J. Architecture of the Human and Yeast General Transcription and DNA Repair Factor TFIIH. Mol Cell. 2015 Sep 03; 59(5):794-806.
-
Allan JM, Smith AG, Wheatley K, Hills RK, Travis LB, Hill DA, Swirsky DM, Morgan GJ, Wild CP. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood. 2004 Dec 15; 104(13):3872-7.
-
Yankulov KY, Pandes M, McCracken S, Bouchard D, Bentley DL. TFIIH functions in regulating transcriptional elongation by RNA polymerase II in Xenopus oocytes. Mol Cell Biol. 1996 Jul; 16(7):3291-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|